AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones Lausanne, Switzerland, 12 May 2026 -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune at the upcoming Annual General Meeting (AGM) to spend more time with her family. AC Immune's Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.